OBJECTIVES: This review examines the burden and patterns of disease in systemic lupus
erythematosus (SLE) and the influence and interactions of gender, ethnicity, age, and …

Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying
antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA). …

Objective Antiphospholipid Syndrome Alliance For Clinical Trials and International
Networking (APS ACTION) is an international research network devoted to conducting well‐designed …

Objective To assess whether hydroxychloroquine can delay renal damage development in
lupus nephritis patients. Methods Lupus nephritis patients (n = 256) from the LUpus in …

Objective. Damage accrual in SLE has been previously shown to be an independent predictor
of mortality. We sought to discern which SLICC Damage Index (SDI) domains are the …

Introduction: Systemic lupus erythematosus (SLE) is a disease distributed worldwide, which
occurs in both genders, and across racial/ethnic and age groups; however, higher rates are …

The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the
occurrence of venous and/or arterial thrombosis and pregnancy morbidity in the presence of …

Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease,
represents a significant challenge for both diagnosis and treatment. Patients with SLE in …

Aim To determine characteristics associated with more severe outcomes in a global registry
of people with systemic lupus erythematosus (SLE) and COVID-19. Methods People with …

Purpose To determine the association between the number of flares systemic lupus
erythematosus (SLE) patients experience and damage accrual, independently of other known risk …